Halozyme Therapeutics

HALO

Halozyme Therapeutics is a U.S. biotechnology company that develops novel oncology therapies designed to target the tumor microenvironment and licenses a novel drug delivery technology through corporate partnerships. The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California.

Halozyme Therapeutics has been a target of short sellers for a while. The current short interest of 13.11% is roughly at the average of the last 12 months (11.71%).